AZD5363 in combination with fulvestrant in AKT1-mutant ER-positive metastatic breast cancer

被引：0
|
作者：
Smyth, Lillian M.
Oliveira, Mafalda
Ciruelos, Eva
Tamura, Kenji
El-Khoueiry, Anthony
Mita, Alain
You, Benoit
Renouf, Daniel J.
Sablin, Marie-Paule
Lluch, Ana
Mayer, Ingrid A.
Bando, Hideaki
Yamashita, Hiroko
Ambrose, Helen
de Bruin, Elza
Carr, T. Hedley
Corcoran, Claire
Foxley, Andrew
Lindemann, Justin P. O.
Maudsley, Rhiannon
Pass, Martin
Rutkowski, Andrzej
Schiavon, Gaia
Banerji, Udai
Scaltriti, Maurizio
Taylor, Barry S.
Chandarlapaty, Sarat
Baselga, Jose
Hyman, David M.
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Barcelona, Spain
[3] Hosp Univ 12 Octubre, Madrid, Spain
[4] Natl Canc Ctr, Tokyo, Japan
[5] Univ Southern Calif, Los Angeles, CA USA
[6] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA
[7] Univ Lyon 1, Inst Cancerol, Hosp Civils Lyon, CITOHL, Lyon, France
[8] British Columbia Canc Agcy, Vancouver, BC, Canada
[9] Inst Curie, Paris, France
[10] Inst Curie, St Cloud, France
[11] Hosp Clin Univ, Valencia, Spain
[12] INCLIVA Hlth Res Inst, Valencia, Spain
[13] Univ Valencia, Valencia, Spain
[14] CIBERONC ISCIII, Valencia, Spain
[15] Vanderbilt Breast Ctr, Nashville, TN USA
[16] Hosp East, Natl Canc Ctr, Chiba, Japan
[17] Hokkaido Univ Hosp, Sapporo, Hokkaido, Japan
[18] AstraZeneca, Cambridge, England
[19] Inst Canc Res, London, England
[20] Royal Marsden NHS Fdn Trust, London, England
来源：
CANCER RESEARCH | 2018年 / 78卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P5-21-32
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Capivasertib (AZD5363) in combination with fulvestrant in PTEN-mutant ER plus metastatic breast cancer
    Smyth, Lillian M.
    Batist, Gerald
    Meric-Bernstam, Funda
    Kabos, Peter
    Spanggaard, Iben
    Lluch, Ana
    Schram, Alison
    Varga, Andrea
    Wong, Andrea
    Ambrose, Helen
    Barnicle, Alan
    Carr, T. Hedley
    de Bruin, Elza C.
    Salinas-Souza, Carolina
    Foxley, Andrew
    Hauser, Joana
    Lindemann, Justin P. O.
    Maudsley, Rhiannon
    McEwen, Robert
    Moschetta, Michele
    Roudier, Martine
    Schiavon, Gaia
    Razavi, Pedram
    Banerji, Udai
    Chandarlapaty, Sarat
    Baselga, Jose
    Hyman, David M.
    CANCER RESEARCH, 2020, 80 (04)
  • [2] Durable Control of Metastatic AKT1-Mutant WHO Grade 1 Meningothelial Meningioma by the AKT Inhibitor, AZD5363
    Weller, Michael
    Roth, Patrick
    Sahm, Felix
    Burghardt, Isabel
    Schuknecht, Bernhard
    Rushing, Elisabeth J.
    Regli, Luca
    Lindemann, Justin P.
    von Deimling, Andreas
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2017, 109 (03):
  • [3] AZD5363 HAS CLINICAL ACTIVITY IN PATIENTS WITH AKT1-MUTANT SOLID TUMORS
    Hyman, D. M.
    Smyth, L. M.
    Donoghue, M. T. A.
    Westin, S. N.
    Bedard, P. L.
    Dean, E. J.
    CANCER DISCOVERY, 2017, 7 (07) : 662 - 662
  • [4] Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer
    Lillian M. Smyth
    Gerald Batist
    Funda Meric-Bernstam
    Peter Kabos
    Iben Spanggaard
    Ana Lluch
    Komal Jhaveri
    Andrea Varga
    Andrea Wong
    Alison M. Schram
    Helen Ambrose
    T. Hedley Carr
    Elza C. de Bruin
    Carolina Salinas-Souza
    Andrew Foxley
    Joana Hauser
    Justin P. O. Lindemann
    Rhiannon Maudsley
    Robert McEwen
    Michele Moschetta
    Myria Nikolaou
    Gaia Schiavon
    Pedram Razavi
    Udai Banerji
    José Baselga
    David M. Hyman
    Sarat Chandarlapaty
    npj Breast Cancer, 7
  • [5] Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer
    Smyth, Lillian M.
    Batist, Gerald
    Meric-Bernstam, Funda
    Kabos, Peter
    Spanggaard, Iben
    Lluch, Ana
    Jhaveri, Komal
    Varga, Andrea
    Wong, Andrea
    Schram, Alison M.
    Ambrose, Helen
    Carr, T. Hedley
    de Bruin, Elza C.
    Salinas-Souza, Carolina
    Foxley, Andrew
    Hauser, Joana
    Lindemann, Justin P. O.
    Maudsley, Rhiannon
    McEwen, Robert
    Moschetta, Michele
    Nikolaou, Myria
    Schiavon, Gaia
    Razavi, Pedram
    Banerji, Udai
    Baselga, Jose
    Hyman, David M.
    Chandarlapaty, Sarat
    NPJ BREAST CANCER, 2021, 7 (01)
  • [6] Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1E17K-Mutant, ER-Positive Metastatic Breast Cancer
    Smyth, Lillian M.
    Tamura, Kenji
    Oliveira, Mafalda
    Ciruelos, Eva M.
    Mayer, Ingrid A.
    Sablin, Marie-Paule
    Biganzoli, Laura
    Ambrose, Helen J.
    Ashton, Jack
    Barnicle, Alan
    Cashell, Des D.
    Corcoran, Claire
    de Bruin, Elza C.
    Foxley, Andrew
    Hauser, Joana
    Lindemann, Justin P. O.
    Maudsley, Rhiannon
    McEwen, Robert
    Moschetta, Michele
    Pass, Martin
    Rowlands, Vicky
    Schiavon, Gaia
    Banerji, Udai
    Scaltriti, Maurizio
    Taylor, Barry S.
    Chandarlapaty, Sarat
    Baselga, Jose
    Hyman, David M.
    CLINICAL CANCER RESEARCH, 2020, 26 (15) : 3947 - 3957
  • [7] AKT antagonist AZD5363 targets estrogen receptor (ER) function in endocrine resistant breast cancer (BC) and synergises with fulvestrant in vivo
    Martin, Lesley-Ann
    Guest, Stephanie K.
    Pancholi, Sunil
    Ribas, Ricardo
    Gao, Qiong
    Simigdala, Nikiana
    Rani, Aradhana
    Davies, Barry
    Johnston, Stephen
    Dowsett, Mitch
    CANCER RESEARCH, 2015, 75
  • [8] Capivasertib (AZD5363) Plus Fulvestrant Versus Placebo Plus Fulvestrant After Relapse or Progression on an Aromatase Inhibitor in Metastatic ER-Positive Breast Cancer (Faktion): a Randomized, Double-Blind, Placebo-Controlled, Phase II Trial
    Tio, Joke
    Kokornaczyk, Artur
    Tschalener, Bjoern
    Jones, Rober Hugh
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 9 - 9
  • [9] Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER+ Invasive Breast Cancer (STAKT)
    Robertson, John F. R.
    Coleman, Robert E.
    Cheung, Kwok-Leung
    Evans, Abigail
    Holcombe, Chris
    Skene, Anthony
    Rea, Daniel
    Ahmed, Samreen
    Jahan, Ali
    Horgan, Kieran
    Rauchhaus, Petra
    Littleford, Roberta
    Cheung, S. Y. Amy
    Cullberg, Marie
    de Bruin, Elza C.
    Koulai, Loumpiana
    Lindemann, Justin P. O.
    Pass, Martin
    Rugman, Paul
    Schiavon, Gaia
    Deb, Rahul
    Finlay, Pauline
    Foxley, Andrew
    Gee, Julia M. W.
    CLINICAL CANCER RESEARCH, 2020, 26 (07) : 1574 - 1585
  • [10] AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In Vivo
    Ribas, Ricardo
    Pancholi, Sunil
    Guest, Stephanie K.
    Marangoni, Elisabetta
    Gao, Qiong
    Thuleau, Aurelie
    Simigdala, Nikiana
    Polanska, Urszula M.
    Campbell, Hayley
    Rani, Aradhana
    Liccardi, Gianmaria
    Johnston, Stephen
    Davies, Barry R.
    Dowsett, Mitch
    Martin, Lesley-Ann
    MOLECULAR CANCER THERAPEUTICS, 2015, 14 (09) : 2035 - 2048
12345